Moreover, immunoblotting studies of breast cancer cells treated with ambiguine I showed down-regulation of both p65 and p50 subunits of NF-κB, and the upstream kinase, IKKβ; in turn, ambiguine I treatment led to a down-regulation of intracellular cell adhesion protein, ICAM-1, which is involved in migration and invasion of cancer cells, suggesting a potential novel mechanism of the compound as an anticancer drug [65]. Here, NFKB1 is linked to breast cancer.